The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CLSD | -78.79% | -82.17% | -29.17% | -97% |
| S&P | +14.5% | +93.32% | +14.09% | +218% |
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Analysts are excited about the biotech's investigational treatment for a common eye disorder.
Sometimes press release headlines and share prices don't match up.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.49M | 446.7% |
| Gross Profit | $0.41M | 787.0% |
| Gross Margin | 82.93% | 31.8% |
| Market Cap | $62.80M | -35.4% |
| Market Cap / Employee | $1.96M | 0.0% |
| Employees | 32 | 6.7% |
| Net Income | -$4.50M | 40.8% |
| EBITDA | -$3.48M | 53.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.38M | -48.6% |
| Accounts Receivable | $0.82M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $55.85M | 18.3% |
| Short Term Debt | $0.38M | 3.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -112.50% | -21.0% |
| Return On Invested Capital | -129.31% | -13.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.73M | 22.5% |
| Operating Free Cash Flow | -$4.73M | 16.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.73 | -1.87 | -1.54 | -1.29 | -71.07% |
| Price to Sales | 12.32 | 43.30 | 18.76 | 14.95 | 15.77% |
| Price to Tangible Book Value | -40.93 | -30.62 | -27.14 | -20.20 | -69.77% |
| Enterprise Value to EBITDA | -20.70 | -14.78 | -21.69 | -31.32 | 104.86% |
| Total Debt | $49.97M | $52.47M | $54.06M | $56.24M | 18.16% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
